Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Kia EV9 GT marks world debut at LA Motor Show
-
9
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
10
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
iGene Laboratory Announces Launch of Whole Exome Sequencing Service
By PRNEWSWIREPublished : Feb. 21, 2023 - 10:11
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- Singapore-based molecular diagnostics lab group iGene Laboratory announces the launch of FetalExome test service.
FetalExome test is a whole exome sequencing (WES) test available for women with potentially complicated pregnancies. The test examines and analyses the gene regions that code for proteins, known as the exome, which plays a critical role as these proteins form the building blocks of cells and allows specialists to diagnose fetal abnormalities and reveal the causes of fetal complications.
FetalExome is ordered when prenatal ultrasound imaging detects structural anomalies that is suggestive of genetic causes.
Fetal structural anomalies are common and affect about 2-4% of pregnancies. The American College of Medical Genetics and Genomics (ACMG) recommends the use of WES when a diagnosis cannot be obtained using routine prenatal methods in a fetus with one or more significant anomalies.1
FetalExome is offered as a trio analysis where sequencing is performed on both parents and the fetus for timely clinical management and decision-making.2
Chief Executive of iGene Laboratory, Kane Black remarked, "As arguably the fetal-maternal health pioneer in South East Asia, we are proud to launch another test to support mother's to be and their babies". Mr. Black further commented "with thousands of genes analysed at the same time, rather than one or a few genes at a time, FetalExome will allow doctors to potentially identify and/or administer the best specific treatments efficiently".
1. Monaghan KG, Leach NT, Pekarek D, Prasad P, Rose NC; ACMG Professional Practice and Guidelines Committee. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22(4):675-680. doi:10.1038/s41436-019-0731-7
About iGene Laboratory:
iGene Laboratory Pte. Ltd is a College of American Pathologists (CAP) Accredited Next Generation Sequencing Laboratory that provides diagnostic testing, with a focus on women's and fetal Health, clinical research (CRO) and COVID-19 testing services.
The company was the first to launch Non Invasive Prenatal Testing (NIPT) in Singapore and continues today on this foundation of pioneering diagnostics.
iGene Laboratory is a subsidiary of INEX Innovate Pte Ltd, one of Asia's fastest growing molecular diagnostics developers. Founded by veteran maternal fetal medicine specialists, INEX is uniquely positioned to identify and address clinically unmet needs within the fetal health and women's oncology landscape, with a broad commercial portfolio of validated tests and 48 key patents.
For more information please visit: www.igenelab.com or www.inex.sg
